Opinion: Five priorities to remake the FDA in a time of deep uncertainty
Two former FDA leaders look at Commissioner Marty Makary’s early stumbles — and lay out a list of priorities to protect both Americans’ health and the critical biotech industry.
The first few weeks in office are never easy, but the early stumbles of Marty Makary, the new commissioner of the Food and Drug Administration under the second Trump administration, are cause for concern. Confirmed swiftly, he enjoyed broad support from the biotech industry, which hoped that he would usher in a new era of scientific leadership at the agency.
Instead, he inherited an embattled FDA just days after sweeping budget cuts mandated by the Department of Government Efficiency (DOGE) rattled the agency’s workforce and shocked the life sciences sector.
